Fate Therapeutics, Inc.
FATE
$1.08
$0.087.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -8.70% | 17.07% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -8.70% | 17.07% | |||
| Cost of Revenue | 576.21% | -86.89% | |||
| Gross Profit | -1,158.99% | 93.04% | |||
| SG&A Expenses | -7.05% | -16.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.17% | -9.40% | |||
| Operating Income | 6.04% | 10.45% | |||
| Income Before Tax | 5.34% | 9.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.34% | 9.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.34% | 9.44% | |||
| EBIT | 6.04% | 10.45% | |||
| EBITDA | 6.48% | 11.22% | |||
| EPS Basic | 5.71% | 9.57% | |||
| Normalized Basic EPS | 5.73% | 9.52% | |||
| EPS Diluted | 5.71% | 9.57% | |||
| Normalized Diluted EPS | 5.73% | 9.52% | |||
| Average Basic Shares Outstanding | 0.40% | 0.13% | |||
| Average Diluted Shares Outstanding | 0.40% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||